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Abstract 
Macroautophagy has recently emerged as an important catabolic process involved not 
only in innate immunity but also in adaptive immunity. Initially described to deliver 
intracellular antigens to MHC class II loading compartments, its molecular machinery has 
now also been described to impact the delivery of extracellular antigens to MHC class II 
loading compartments through the non-canonical use of the macroautophagy machinery 
during LC3-associated phagocytosis (LAP)(1). Therefore, in pathological situations (viral 
or bacterial infections, tumorigenesis) the pathway might be involved in shaping CD4+ T 
cell responses.  
 In this chapter we describe three basic experiments for the monitoring and 
manipulation of macroautophagic antigen processing towards MHC class II presentation 
through the canonical pathway. Firstly, we will discuss how to monitor autophagic flux 
and autophagosome fusion with MHC class II loading compartments. Secondly, we will 
show how to target proteins to autophagosomes in order to monitor macroautophagy 
dependent antigen processing via their enhanced presentation on MHC class II molecules 
to CD4+ T cells. And finally, we will describe how macroautophagy can be silenced in 
antigen presenting cells, like human monocyte-derived dendritic cells (DCs). 
 
Key words: 
Macroautophagy,  CD4+ T cells,  MHC class II loading compartment 
 
1. Introduction 
Since antigen processing for MHC presentation to T cells relies on cellular proteolytic 
systems, like lysosomes for MHC class II and proteasomes for MHC class I presentation 
(2, 3), cellular transport pathways that deliver proteins to these catabolic machineries can 
contribute to immune surveillance by T cells. Autophagy is no exception. It describes at 
least three pathways, by which cytoplasmic constituents gain access to lysosomal 
degradation. These are chaperone-mediated, micro- and macroautophagy (4). Both 
chaperone-mediated and microautophagy rely on substrate recognition by HSC70 
chaperones, and proteins selected for it carry a pentameric recognition sequence (5, 6). 
For chaperone-mediated autophagy HSC70 docks to LAMP2a in the lysosomal 
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membrane and the substrates are then translocated across this membrane with the help of 
luminal HSP70 chaperones. For microautophagy, substrate carrying HSC70 molecules 
attach to late endosomal membranes, which then bud into the endosomal lumen, and 
endosome-lysosome fusion then delivers this cargo for degradation. While chaperone-
mediated and microautophagy degrade only soluble proteins, macroautophagy is able to 
deliver larger protein aggregates and whole cell organelles for lysosomal degradation (7). 
For this purpose, a cup-shaped isolation membrane forms around the autophagic cargo to 
finally engulf it completely in a double membrane surrounded autophagosome. This 
autophagosome then fuses with lysosomes for degradation of its content and the inner 
autophagosomal membrane. This process requires more than 30 so-called autophagy 
related genes (atgs), which were originally described in yeast, but have now also been 
identified in higher eukaryotes (8). Of these, we will only discuss two complexes in this 
chapter, which are relevant for the described experiments, while a more complete 
description has been given in a recent review (9). The two Atg complexes that are 
primarily targeted for macroautophagy monitoring and manipulation, center around the 
two ubiquitin-like molecules Atg8 with its main mammalian homologue LC3, and Atg12. 
Atg12 gets conjugated to Atg5 by the two E1- and E2-like enzymes Atg7 and 10. The 
resulting conjugate then associates with Atg16L1 at the outer autophagosomal 
membrane. This complex catalyzes ligation of Atg8 to phosphatidylethanolamine (PE), a 
phospholipid in the autophagome membrane. Prior to this coupling, Atg8 gets cleaved by 
Atg4 to liberate a C-terminal glycine residue, which conjugates to PE, and is activated by 
the E1- and E2-like enzymes Atg7 and Atg3. Atg8 is thought to facilitate lipid fusion 
during isolation membrane generation (10) and substrate recruitment (11). While the 
Atg5/12/16L1 complex and Atg8 are recycled from the outer autophagsomal membrane 
upon vesicle completion, Atg8 stays attached to the inner autophagosomal membrane and 
gets degraded with it after fusion with lysosomes. This can be monitored for 
autophagosome visualization and turn-over. Furthermore, primarily Atg5 and 7 are 
targeted to inhibit macroautophagy. 
 Immunologists are mainly interested in macroautophagy for three reasons. It can 
degrade intracellular pathogens (12), modulates pathogen detection (13) and it assists in 
antigen processing for MHC presentation (14). Macroautophagy facilitates MHC 
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presentation to T cells mainly via three pathways. It directly imports antigens into MHC 
class II loading compartments (15), it augments antigen packaging in antigen donor cells 
for efficient cross-presentation (16, 17) and through the non canonical LAP pathway it 
modulates exogenous antigen delivery for MHC class II presentation (18). Intracellular 
antigen processing via macroautophagy might account for 20-30% of natural MHC class 
II ligands that are derived from cytosolic or nuclear proteins (19), including self-protein 
derived peptides that are involved in positive and negative selection of CD4+ T cells in 
the thymus (20). In addition to self-proteins, few viral and bacterial antigens have been 
reported to be processed via macroautophagy for MHC class II presentation (21-24). 
Here we will focus on the classical macroautophagy pathway, while the monitoring of 
antigen presentation through the  non-canonical LAP pathway has been reviewed 
elsewhere (1).  
For the monitoring of the canonical pathway of autophagic antigen processing for 
MHC class II presentation we will describe three experiments. Firstly, we will discuss 
how the tandem GFP-RFP-Atg8/LC3 construct can be used to monitor autophagic flux 
and autophagosome fusion with MHC class II loading compartments (Fig. 1). Secondly, 
we will show how Atg/LC3 fusion proteins can be used to monitor macroautophagy 
dependent antigen processing via their enhanced presentation on MHC class II molecules 
to CD4+ T cells (Fig. 2). And finally, we will describe how macroautophagy can be 
silenced in antigen presenting cells, like human monocyte-derived dendritic cells (DCs), 
via Atg specific siRNA (Fig. 3). These basic experiments allow for the monitoring and 
manipulation of macroautophagic antigen processing towards MHC class II presentation. 
They characterize this specific antigen processing pathway and the level of 
macroautophagy in antigen presenting cells in general. 
 
2.Materials 
2.1. Cell Culture 
2.1.1. Cell lines (see Note 1): 
1. Human embryonic kidney epithelial cell line, HLA-DR4+ HEK 293 (obtained 
from Dr. Rong-Fu Wang, Houston, Texas). 
Gannage, Barreira da Silva and Münz  5 
2. Human lung epithelium cell line A549 (obtained from Dr. Thomas Moran, New 
York, NY). 
3. Human melanoma cell line M199 (obtained from from Dr. Jean-Francois 
Fonteneau, Nantes, France).  
4. Cell culture medium: Dulbecco’s modified Eagle’s medium (DMEM, Gibco,) 
with 10% fetal bovine serum (FBS), 2 mM glutamine, 110 μg/ml sodium 
pyruvate, and 2 μg/ml gentamicin (Gibco). 
2.1.2. Human dendritic cells 
1. PBMCs are isolated from leukocyte concentrates (Zurich Blood Center) by 
density-gradient centrifugation on Ficoll-Hypaque. CD14+ 
monocytes/macrophages are isolated by positive magnetic cell separation 
(Miltenyi Biotec) and differentiated to monocyte-derived DCs with IL-4 and GM-
CSF and matured with appropriate stimuli as described in Section 3.1.2. 
2. Dendritic cell culture medium: RPMI 1640 supplemented with 2% heat-
inactivated pooled human AB serum (Invitrogen), and 2 μg/ml gentamicin 
(Gibco). 
2.1.3. Cytokines 
1. Recombinant human interferon-gamma (IFN-) (Peprotech) is reconstituted in 
sterile H2O + 0.1% human serum albumin (HSA, Sigma) to a concentration of 10 
ng/l and frozen aliquots are kept at -20oC. 
2. Recombinant human interleukin-4 (IL-4) (Peprotech) is reconstituted to a 
concentration of 20 ng/l and frozen aliquots are kept at -20ºC. 
3. Granulocyte–macrophage colony-stimulating factor (GM-CSF) (Invitrogen) is 
reconstituted to a concentration of 20 ng/l and frozen aliquots are kept at -20ºC 
2.2. Antibodies 
2.2.1. Primary antibodies 
1. Maturation of monocyte-derived DCs is monitored by flow cytometry using anti-
CD11c, -CD83, -CD86, -HLA-DR and HLA-ABC antibodies (BD Biosciences). 
2. Expression of MHC class II molecules:  
a) The mouse monoclonal HLA-DR/DP/DQ-specific hybridoma IVA12 
(ATCC). The hybridoma is grown in RPMI-1640 with 10% FBS, 2 mM 
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glutamine, 2 μg/ml gentamicin and supernatant is harvested by spinning 
cells down at 300 x g for 10 min. Supernatant is filtered through a 0.2-μm 
filter and stored at 4oC. Use at a 1:10 dilution. 
b) A mouse monoclonal antibody against human LAMP2 (lysosomal-
associated membrane protein 2) (clone H4B4) antibody (eBioscience) is 
used at 0.5g/ml. 
c) A mouse monoclonal antibody against HLA-DR molecules (clone L243) 
(eBioscience) is used at 1 g/ml. 
3. Expression of LC3 is monitored with: 
a) Rabbit polyclonal anti-LC3 antibody (MBL) use at 1/1000. 
b) Mouse monoclonal anti-LC3 antibody (Clone 5F10) (Nanotools) use at 
1/500. 
2.2.2. Secondary antibodies.  
1. Alexa fluor-555 conjugated goat anti-mouse: to be used at 1/500 dilution. 
2. Alexa fluor-488 conjugated goat anti-rabbit: to be used at 1/500 dilution. 
3. Alexa fluor-647 conjugated rat anti-mouse: to be used at 1/500 dilution. 
4. Alexa fluor-647 conjugated goat anti-mouse: to be used at 1/500 dilution. 
 
2.3 Expression of NY-ESO-LC3 Fusion Construct and the RFP-GFP-LC3 tandem 
construct by transient transfection 
1.Plasmids DNA 
• NY-ESO/LC3 fusion construct is obtained by inserting the human Atg8/LC3 
cDNA sequence (genebank entry NM_022818) and the human NY-ESO-1 cDNA 
sequence NM_001327.1  into the mammalian expression vector pEGFP-C2 (BD, 
Biosciences)  
• NY-ESO-1 (pCMV6-XL4) (Origene) expression vector encoding for the human 
NY-ESO-1 is used in parallel as a control. 
• The fusion mRFP-GFP tandem fluorescent LC3 (tfLC3) construct is obtained 
from Dr. Tamotsu Yoshimori (Osaka, Japan).  
For better transfection results, maxipreps of the different DNA plasmids should be 
prepared and DNA should be eluted in sterile DPBS. DNA concentration and purity is 
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determined by OD260/OD280 absorption spectroscopy in a spectrophotometer. 
OD260/OD280 ratio should be greater than 1.8. DNA and is stored in aliquots at −20oC. 
2. Transient transfection medium: cell culture medium without gentamicin (see Note 2). 
3. Transfecting reagent: Lipofectamine 2000 (Invitrogen). 
4. Transfecting medium: OptiMEM-I (Gibco) without Phenol Red. 
 
2.4. Immunocytochemistry and Confocal Microscopy to Analyze MHC Class II 
Compartments  
1. Circular 1.5-mm cover slips (Fisher) (see Note 3). 
2. 70% (v/v) ethanol  
3. Sterile DPBS. 
4. Chloroquine (CQ) (Sigma) the stock is prepared in water at a concentration of 20 
mM, and frozen aliquots are stored at -20C, the working concentration is 50M 
(i.e. dilute the stock to 1/400) 
5. Fixative solution 4% Paraformaldehyde  
6. Permeabilization solution: 0.1% (v/v) Triton-X 100 in PBS. 
7. Blocking buffer: PBS, 10% normal goat or donkey serum (NDS or NGS from 
Sigma), 0.1% saponin (Calbiochem) (see Note 4).  
8. Staining buffer: PBS, 5% normal goat or donkey serum (NDS or NGS from 
Sigma), 0.1% saponin (Calbiochem)  
9. Washing buffer: 1X PBS. 
10. DAPI nucleic acid staining solution: Prepare a 5 mg/ml stock of 4,6-diamidino-2-
phenylindole (DAPI, Invitrogen-Molecular Probes) in ddH2O and store in 
aliquots at -20ºC. Dilute 1:10000 in PBS to freshly prepare a working solution. 
11. Mounting medium: Prolong Gold Antifade Reagent (Invitrogen-Molecular 
Probes). 
12. Confocal laser scanning microscope, using a high N.A. oil immersion lens (e.g., 
63x/1.4 N.A.) 
13. ImageJ software 
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2.5. MHC Class II Presentation Assay Using a NY-ESO-1 -Specific CD4+ T-Cell 
Clone 
1. A NY-ESO-1 specific CD4+ T-cell clone for the 157-170 epitope of this tumor 
antigen (obtained from Dr. Jean-Francois Fonteneau, Nantes, France) is cultured 
in RPMI-1640 with 8% pooled human serum (PHS, Mediatech Inc.), with 450 
U/ml recombinant human IL-2 (Peprotech), 2 mM glutamine, 2 μg/ml gentamicin 
in round-bottom 96-well plates (see Note 5). 
2. Recombinant human IFN- (Peprotech) as in Section 2.1.3. 
3. Coculture medium: RPMI-1640 with 5% PHS, 2 mM glutamine and 2 μg/ml 
gentamicin. 
4. As positive control the following stimuli is used: specific NY-ESO-1 peptide (1 
mM stock in 10% DMSO, for T-cell stimulation dilute 1:1000 in coculture 
medium) or phyto-hemagglutinin (PHA-L, Sigma, 1 mg/ml stock, for T-cell 
stimulation dilute 1:1000 in coculture medium). 
 
2.6. IFN- ELISA to Analyze Secretion of IFN- by NY-ESO-1 specific clonal CD4+ 
T Cells 
1. High-protein-binding 96-well ELISA plates (e.g., Maxisorp, Nunc). 
2. ELISA kit for human IFN- (Mabtech, Nacka Strand). A 10 μg/ml stock of human 
recombinant IFN- provided with the kit is prepared and frozen in aliquots at -
20oC. A freshly thawed aliquot should be used for each experiment. 
3. coculture medium as in Section 2.5.  
4. Blocking buffer: PBS, 1% BSA (Sigma). 
5. Washing buffer: PBS, 0.05% Tween-20. 
6. Incubation buffer: PBS, 0.1% BSA, 0.05% Tween-20. 
7. TMB peroxidase substrate solution (Sigma) 
8. Stop solution: 1 N sulfuric acid. 
 
2.7. Silencing macroautophagy in dendritic cells 
1. Stealth siRNA: All Stealth™ siRNA duplexes (Invitrogen) are dissolved to a final 
concentration of 100 μM according to the manufacturer's instructions. Scrambled 
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siRNA are ordered for each target sequence. In our case, we used siRNA targeting 
the Atg16L1 sequence: Sense- 5’GAG UUG UCU UCA GCC CUG AUG GCA 
G3’ and Anti-Sense-5’CUG CCA UCA GGG CUG AAG ACAACUC3’ 
2. Electroporation medium: Opti-MEM without phenol red (Invitrogen). 
3. 4mm electroporation cuvette (Biorad). 
4. Electroporator: ECM830 Square Porator TM 
 
3. Methods 
3.1. Cell Culture 
3.1.1. Cell lines 
1. A549, M199 and HLA-DR4+ HEK 293 cells are maintained in 100mm plates until 
they approached confluence. 
2. To split cells, monolayers are washed once with 5 ml of DPBS and incubated with 
2 ml of 0.025 % trypsin/EDTA solution at 37ºC for 2–3 min to detach cells. To 
set up new maintenance cultures, the cells are re-plated at 1/5 for M199 and 
A549, and at 1/10 for HLA-DR4+ HEK 293 and fresh culture medium is added. 
These cultures approach confluence after 2–3 days. 
3. To induce expression of the MHC class II antigen processing machinery in the 
M199 cell line, cells are cultured with 200 units/ml of IFN, for 48 hours. At least 
50% of cells express MHC class II on their cell surface after this treatment. 
3.1.2. Monocyte-derived dendritic cells 
1. PBMCs are isolated from leukocyte concentrates by density-gradient 
centrifugation on Ficoll/Hypaque.  
2. CD14+ monocytes are isolated from PBMCs by positive magnetic cell separation 
(Miltenyi Biotec), then plated in 6 well plates at a density of 2-3x106 cells per 
well, in a final volume of 3 ml, and cultured for 5 days in dendritic cell medium  
(RPMI 1640 supplemented with 2% heat-inactivated pooled human AB serum 
(Invitrogen)). GM-CSF and (IL)-4 are added to the culture on days 0, 2, and 4, 
each at a final concentration of 20 ng/ml. 
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3. On day 5 immature DCs are collected after pipetting up and down each well at 
least 20 times with a 1ml pipette. Remaining adherent cells should not be 
collected. 
4. Cells are then counted and plated in a 12 well plate at a concentration of 1 million 
cells/ml and matured with the appropriate stimuli (in our case influenza infection).  
5. Matured dendritic cells are collected at day 6 and their maturation phenotype 
checked by FACS analysis.  
 
3.2. Expression of NY-ESO-LC3 or the tandem RFP-GFP-LC3 Fusion Construct by 
Transient Transfection 
1. To set cells up for transfection, cells are detached as described in Section 3.1.1. 
step 2 and plated in 6-well tissue culture plates in transient transfection medium 
at a density of 2-3x105 cells/well (see Note 2). 
2. The next day, cultures should be about 70–80% confluent. 
a) For each well to be transfected, 2.5 μg plasmid DNA are diluted in 250 μl 
OptiMEM-I medium and mixed by vortexing briefly. 
b) In a separate tube, 5 μl lipofectamine 2000 are diluted in 250 μl 
OptiMEM-I medium and vortexed briefly. 
c) Both tubes are incubated for 5 min at room temperature. 
d) Both solutions are combined and briefly vortexed, followed by incubation 
for 20 min at room temperature to allow formation of DNA–lipofectamine 
complexes. 
3. Complexes are then added in a dropwise manner to the culture medium of cells in 
the 6-well plate and incubated at 37oC for 4 hours.  
4. After 4 hours, the complex-containing medium is replaced with fresh culture 
medium, and cells are cultured for 18–20 h at 37oC (see Note 6). 
5. Twenty-four hours post transfection, cells are ready to be split onto microscopy 
cover slips for localization analysis by confocal immunofluorescence microscopy 
(see Section 3.3) or for use in MHC presentation assays (see Section 3.4). 
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3.3. Immunocytochemistry and Confocal Microscopy to analyse autophagosomes 
flux and MHC Class II Compartment  
1. Round 1.5-mm microscopy cover slips are placed into 24-well tissue culture plate. 
Eight extra cover slips are used for control stainings (see Note 7). 
2. Cover slips are then sterilized by washing once with 70% ethanol and twice with 
sterile DPBS. Any traces of ethanol are removed by completely aspirating ethanol 
and wash solutions with a vacuum suction flask. 
3. Cells, transfected with the mRFP-GFP tandem fluorescent LC3 (tfLC3) construct 
(see Section 3.2.), are trypsinized and plated onto sterilized cover slips in cell 
culture medium, at a density of 200000 cells/well. Two wells of each sample 
should be plated, so that cells could be analyzed with and without chloroquine 
(CQ) treatment or Toll like receptor stimulation. 
4. During the last 24h of the culture, one set of cells are treated with 50 μM CQ to 
prevent degradation of the tfLC3 construct by lysosomal proteases, or/and the 
cells are stimulated with the TLR agonist or infected with the pathogen of interest 
depending on the experimental set up (in our case influenza infection for 24 
hours). Leave at least 2 wells of cells untreated as a control (see Note 7). 
5. Cells are then washed once in PBS (0.5 ml/well) and fixed in 4% 
paraformaldehyde (PFA, 200 μl/well) for 15 min at room temperature (see Note 
8). 
6. Then cells are washed once in PBS (0.5 ml/well) and permeabilized in 0.1% 
Triton X-100 (200 μl/well) for 5 min. 
7. Next, cells are washed once in PBS (0.5 ml/well) and blocking buffer (200 
μl/well) is added for 30 min. 
8. The primary antibodies are diluted in blocking buffer and added to cells (200 
μl/well) for 45 min at room temperature or for longer periods (up to overnight) at 
4ºC. Co-staining of LC3 and MHC class II compartment is possible by using the 
anti-LC3 rabbit antibody and one of the mouse antibodies specific for MHC class 
II compartment.  
9. Then cells are washed three times in washing buffer (0.5 ml/well) and incubated 
for 5 min each time. 
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10. The secondary antibodies are diluted in blocking buffer and added to cells (200 
μl/well) for 30 min. 
11. Secondary antibody solutions are then aspirated and DAPI nucleic acid stain is 
added for 1 min (200 μl/well). Afterwards, cells are immediately washed. 
12. Cells are then washed once in PBS and cover slips are mounted on microscopy 
slides by inverting them onto a drop of mounting medium on a microscopy slide, 
up to three cover slips per slide. Next, cover slips are carefully press down, excess 
mounting medium is aspirated and slides dry at room temperature in the dark (see 
Note 9). Afterwards, slides could be stored in the dark at 4ºC for several months. 
13. Slides are then analyzed with a confocal laser scanning microscope, using a high 
N.A. oil immersion lens (e.g., 63x/1.4 N.A.). Excitation at 405 nm elicited DAPI 
fluorescence (blue emission), excitation at 488 nm Alexa 488 fluorescence, or 
GFP (green emission), and excitation at 543 nm RFP or Alexa 555 fluorescence 
(red emission). Image J Software or Imaris Software are  used to overlay the 
different fluorescence channels and to quantify colocalization (see Note 10). Two 
experiments are shown as an example in Figure 1: An experiment with influenza 
virus matrix protein 2 (MP2) transfection of A549 cells expressing the tandem 
RFP-GFP-LC3 construct is shown in Fig. 1A. In Fig.1B an example of MHC 
class II staining of HEK 293 cells that were infected with influenza A virus is 
shown. 
 
3.4. MHC Class II Presentation Assay Using a NY-ESO-1 Specific CD4+ T-Cell 
Clones 
1. For MHC class II presentation assays, HLA-DR4+ HEK 293 or M199 cells 
transfected with the two different NY-ESO-1 constructs (see Section 2.3) in a 6-
well format are used, as described in Section 3.2. M199 cells are treated with 200 
U/ml IFN- for 48 hours to initiate expression of the MHC class II antigen 
processing machinery. 
2. Any traces of IFN- are removed from cells by washing cell monolayers three 
times in RPMI-1640 medium. Then cells are trypsinized to prepare a cell 
suspension, washed once in coculture medium and counted with a 
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hemacytometer. Cell suspensions are prepared in co-culture medium at three 
different cell concentrations (2x105, 105 and 6.67x 104 cells/ml) (see Note 11). 
3. NY-ESO-1 specific clonal CD4+ T cells are collected from 96-well culture plates, 
washed once in coculture medium and counted. The cell concentration is adjusted 
to 2x106 cells/ml. 
4. Cocultures of T cells and target cells are set-up in duplicates (2 wells/condition) 
in a 96-well round-bottom plate. Per well, 50 μl of T-cell suspension (105 
cells/well) and 100 μl of the different target cell suspensions (2x105, 105 and 
6.67x104 cells/ml) are added. This results in effector to target (E:T) ratios of 5, 10 
and 15. As a positive control, clonal T cells are stimulated with the cognate NY-
ESO-1 peptide (1 μM) or PHA-L (1 μg/ml). As a negative control, clonal T cells 
are exposed to coculture medium alone. 
5. Cells are then cultured overnight (18–24 h) at 37 ºC. 
 
3.5. IFN- ELISA to analyze secretion of IFN- by NY-ESO-1 specific clonal CD4+ T 
cells  
1. One day prior to ELISA, high-protein-binding ELISA plates are coated with a primary 
anti-IFN- antibody (1-D1K, included in IFN- ELISA kit), diluted 1:500 in PBS, 100 
μl/well. Plates are then incubated overnight at 4 ºC. 
2. The next day, the plates are washed two times with PBS (200 μl/well) and blocked 
with blocking buffer (200 μl/well) for 1 h at room temperature. 
3. An aliquot of IFN- standard (10 μg/ml) is thawed and serial dilutions are prepared in 
coculture medium (prepare 2000, 1000, 500, 250, 125, 62.5, 31.25 pg/ml standards, at 
least 300 μl each). 
4. To make sure that IFN- secreted by T cells is homogeneously distributed in culture 
supernatants, supernatants are mixed by pipetting up and down with a multichannel pipet 
and cells are then pelleted by centrifugation of plates at 300g for 5 min. 
5. With a multichannel pipet, 120 μl of supernatant are carefully removed from each well 
and transferred to a new 96-well plate. 
6. ELISA plates are washed four times with washing buffer. 
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7. The coculture supernatants or IFN- standards (100 μl/well) are then added and 
incubated for 2 hours at room temperature. The remaining 20 μl of supernatant are frozen 
at –20oC in case ELISA has to be repeated on diluted supernatants (see Note 13). 
8. Plates are then washed as in step 6 and 100 μl/well of secondary antibody (7-B6-1-
biotin, provided in ELISA kit) are added, diluted 1:1000 in incubation buffer. An 
incubation time of one hour at room temperature follows. 
9. Again, plates are washed as in step 6 and 100 μl/well of streptavidin-HRP (provided in 
ELISA kit) are added, diluted 1:1000 in incubation buffer. Another hour at room 
temperature is observed as incubation time. 
10. As in step 6 plates are washed again and 100 μl/well of TMB peroxidase substrate is 
added. The plates are incubated until blue reaction product has sufficiently developed, 
then the reaction is stopped by adding 100 μl/well of Stop solution. 
11. Optical density is measured at 450 nm (OD450) in an ELISA plate reader and OD450 
values are converted into IFN- concentration in pg/ml, using the IFN- standards (see 
Note 12). An example of the produced results is shown in Fig. 2. 
 
3.6. Silencing Macroautophagy in Monocytes-derived Dendritic Cells 
1. Electroporation of immature monocyte-derived DCs with siRNA targeting Atg16L1 or 
Atg5 or scrambled siRNA is performed at day 4 (see Note 13 and Note 14). For this 
purpose, immature DCs are collected after pipetting up and down each well at least 20 
times with a 1ml pipette, and then washed once in RPMI without serum. Remaining 
adherent cells should not be collected.  
2. Cells are adjusted to a final concentration of 3-4x106 immature DCs/ in 200 l Opti-
MEM medium without phenol red, and transferred to an electroporation cuvette. The 
cells are kept at 4oC until the electroporation step. 
3. One nmol of the siRNA of interest (Atg16L1 in our case or the scrambled control 
siRNA) is added to the cells directly in the 4 mm cuvette on ice just prior to 
electroporation.  
4. The cells are then electroporated in an ECM830 Square Porator TM with a unique 
square wave pulse of 500V 0.5ms.  
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5. Cells are then plated at a density of 1 million cells/ml in a 12 well plate in R2 medium 
supplemented with GM-CSF and IL-4. 
6. Maturation of these immature DCs is performed the next day, at day 5, using the 
maturation stimuli of interest (in our case influenza A infection).  
7. At day 6 matured dendritic cells are collected for analysis. Maturation phenotype and 
viability of the cells are checked by FACS analysis (see Note 15). 
8. Immunocytochemistry and microscopy are then performed as described in Section 3.3. 
 
4. Notes 
1. Cell lines are chosen based on their ability to up-regulate MHC class II expression 
upon IFN- treatment and their MHC class II expression matching the restriction 
of the used T cell clone. The M199 cell line carries HLA-DP4 and the used CD4+ 
T cell clone is restricted by both DR4 and DP4 molecules. Therefore, HLA-DR4+ 
HEK293 cells are also used in some experiments. 
2. For transfection with lipofectamine 2000, cell culture medium should not contain 
any antibiotics. Therefore, gentamicin is omitted for the transfection. 
3. Non-adherent cells are cytospinned on 1.5 mm coverslips that are pre-coated with 
L-polylysine (Sigma). 
4. Normal donkey or goat sera are used as blocking reagents because secondary 
antibodies are derived from donkey or goat. For secondary antibodies from 
different species 5% normal serum from that species should be used as blocking 
reagent. Alternatively, 5% BSA could be employed as blocking solution. 
5. T cell clones are expanded in RPMI-1640 + 8% PHS + 150 U/ml rhIL-2 (Chiron) 
+ 1 μg/ml PHA-L (Sigma), in 96-well U bottom plates. Up to 1x104 clonal T 
cells/ well, 105 irradiated allogeneic irradiated PBMCs/well and 104 irradiated 
LCLs/well are added as feeder cells. T cell clones should not be used prior to 2 
weeks after re-expansion to allow the T cells to rest after proliferation and avoid 
high background reactivity. 
6. The transfection medium should be changed after 4 hours not only to improve the 
viability of the transfected cells, but also to prevent autophagosome accumulation 
due to an effect of the lipofectamine 2000 transfection reagent. 
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7. For correct interpretation of results, the following control stainings should be 
included: 
a) Primary and secondary antibodies should be replaced with blocking 
buffer. These stainings should be completely negative. 
b) Primary antibody should be replaced with blocking buffer, but secondary 
antibodies should be used. Background from secondary antibodies should 
be low. If the background turns out to be too high, the concentration of the 
secondary antibodies must be lowered. 
c) Untransfected cells and cells that are not treated with IFN- or with 
TLR/maturation stimuli are used as controls. 
d) Single-labeling of cells should be performed and signal bleed-through into 
non-specific neighbouring fluorescence channels should be checked (red 
channel for Alexa488 labeling and green channel for Rhodamine-Red X or 
Alexa555 labelings). There should be no signal in these channels. 
8. From the fixation step onwards, cells could be handled outside sterile biosafety 
cabinets on a laboratory bench. Vacuum suction flasks can be used to change 
solutions, but the plastic tip of suction device should be exchanged between 
different solutions (e.g., antibodies). All incubation steps are done at room 
temperature, unless noted otherwise. 
9. Prolong Gold antifade mounting medium (Invitrogen-Molecular Probes) should 
be allowed to dry at room temperature, in the dark, overnight. During this time, 
the mounting medium solidifies and its refractive index increases. Sealing of 
cover slips with nail polish is not necessary for Prolong Gold, but is 
recommended for other, water-based mounting media. 
10. If a confocal microscope is not available, alternatively slides can be analyzed with 
a conventional wide-field fluorescence microscopes with a motorized z-stage. To 
remove out-of-focus light and accurately analyze colocalization of fluorochromes, 
z-stacks subsequently have to be deconvoluted using a deconvolution software. 
11. The optimal number of target cells per clonal T cell may vary, depending on the 
T-cell clone and the type of target cell. Therefore it is recommended to try a range 
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of different effector and target cell numbers, ranging from 104 to 2x105 T 
cells/well and 103 to 105 target cells/well. 
12. In case IFN- levels in supernatants exceed the linear range of the ELISA 
(approximately 20–1000 pg/ml), frozen supernatants are diluted 1:10 in coculture 
medium and the ELISA assays are repeated. 
13. In case of ATG proteins, it is optimal to perform the knock down 48 hours prior 
to the analysis, since the half life of these protein is usually >24 hours. 
14. In order to discriminate between LAP and the canonical macroautophagy pathway 
selected siRNAs could be used. Molecules required exclusively for the canonical 
pathway are ULK1, FIP200, ATG13, Ambra1, WIPI2 and ATG14. In parallel 
Rubicon and NOX2 are only activated in the LAP pathway. All the other 
components of the formation of autophagosomes are common to both pathways, 
in particular the ATG5/12/16L complex. However, the LAP process is mainly 
activated by phagocytosis of stimuli for TLR2 and Dectin-1 during fungal 
infections, Fc receptor mediated up-take of immune complexes or by TIM4 
mediated phagocytosis of apoptotic debris (1). 
15. Electroporation of dendritic cells can result in up to 30-40% of cell death. 
Therefore it is mandatory to control for cell viability and maturation phenotype of 
your DCs prior to any functional assay. Alternatively if available the use of the 
NeonTM transfection system from Invitrogen is less aggressive to the cells and 
result in significantly less mortality of DCs post transfection. 
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Figure 1: The mRFP-GFP-LC3 reporter construct was used to monitor 
autophagosomes turnover. Lysosomal turnover of autophagosomes was impaired in 
influenza virus MP2 transfected cells, and autophagosomes did not colocalize with 
MHC class II loading compartment after influenza A virus infection. 
A) The tandem reporter construct mRFP-GFP-Atg8/LC3 was transiently transfected into 
influenza A virus matrix protein 2 (MP2) or nucleoprotein (NP) transfected A549 human 
lung epithelial cells. GFP (sensitive to acidification and lysosomal degradation) and RFP 
fluorescence (insensitive to acidification and lysosomal degradation) of the reporter 
construct were analyzed by fluorescence microscopy. DAPI was used to stain nuclear 
DNA. Scale bar: 60 m. One of three experiments is shown. 
The GFP moiety of the tandem construct is sensitive to lysosomal proteolysis and 
quenching in acidic pH, while the mRFP is not. Therefore, the green fluorescent 
component of the composite yellow fluorescence for the mRFP-GFP-LC3 reporter was 
lost upon autophagosome fusion with lysosomes. This fluorescence change from yellow 
to red can be used to visualize lysosomal proteolysis and localization in acidified 
compartments of macroautophagy targeted GFP. 
In NP transfected lung epithelial cells few yellow autophagosomes, but a high number of 
mRFP positive autolysosomes could be detected after transient transfection of mRFP-
GFP-Atg8/LC3 .  
In  MP2 transfected cells in contrast,  there is an accumulation of mRFP and GFP double 
positive vesicles, especially in the perinuclear region, suggesting impaired 
autophagosomes fusion with lysosomes. 
B) HLA-DR4+ HEK 293 cells were infected with influenza A virus for 24 hours, cells 
were then fixed and stained with antibodies specific for MHC class II loading 
compartments (in the upper panel LAMP2). Autophagosomes were excluded from 
LAMP2 positive compartments.  
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Figure 2: MHC class II presentation assay using LC3 targeted antigen: example of 
NY-ESO-LC3   
A) NY-ESO-1 specific clonal CD4+ T cells were co-cultured at various effector to target 
cell (E:T=5:1, black bars; E:T=10:1, grey bars; E:T=15:1, white bars) ratios with the 
M199 melanoma cell line transfected with either NY-ESO-1, or NY-ESO-1-LC3 
constructs. The next day, IFN- was measured in culture supernatants by ELISA to assess 
antigen presentation of NY-ESO-1 on MHC class II molecules. MHC class II 
presentation of the cognate NY-ESO-1 epitope was significantly enhanced by the 
Atg8/LC3 fusion. Error bars indicate standard deviations. One of three experiments is 
shown. Peptide pulsed targets (striped bars) and non-pulsed targets (far right) were used 
as positive and negative controls. 
 
Figure 3: Silencing macroautophagy in monocyte-derived dendritic cells 
Immunofluoresence analysis of autophagosome accumulation (LC3) in immature DCs 
and influenza virus-infected DCs pre-treated with Atg16L1 siRNA or control scrambled 
siRNA: Immature DCs were pretreated at day 4 with siRNA against Atg16L1 or with a 
control siRNA. At day 5, cells were infected with 0.1 HA unit of influenza A virus (PR8). 
At day 6, cells were harvested and fixed for immunostaining with a LC3 specific 
antibody. Upon treatment with Atg16L1 siRNA the accumulation of autophagosomes 
after influenza A virus infection was down-regulated.  One experiment out of 2 is shown. 
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